microbiome

R&D

Why gut bacteria is the next frontier in medicine

Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.

R&D

JP Morgan 2024 – Jonah Comstock interview with Xavier Duportet

JP Morgan 2024 – Xavier Duportet

There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome.

News

Vedanta scores $106.5m to take microbiome drug into ph3

In the face of a challenging biotech financing environment, Vedanta Bio has ra

News

FDA accepts review of SeresTx BLA for oral microbiome therap...

The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral

Events

Partner Content

6th Microbiome Movement - Drug Development Summit Europe

New generation of microbiome-targeted therapeutics

News

Nestle gets closer to Seres, pledging $525m for microbiome C...

Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for

Why gut bacteria is the next frontier in medicine

JP Morgan 2024 – Xavier Duportet

Vedanta scores $106.5m to take microbiome drug into ph3

FDA accepts review of SeresTx BLA for oral microbiome therap...

6th Microbiome Movement - Drug Development Summit Europe

Nestle gets closer to Seres, pledging $525m for microbiome C...

J&J's oral IL-23 drug backed for psoriasis in EU

Discover a new era of healthcare panel engagement: Grounded ...

microbiome

Editor's Picks